Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2020 Q1- Text added to 2020 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
acneiform, adalimumab, ascending, baseline, bilateral, BMS, Center, certified, confirmed, deficient, deliver, dMMREC, dry, EGFRi, elongation, endoscopic, epidemic, epidermal, Festival, Framework, Harbor, Humira, ill, imsidolimab, incapacitated, inherited, kinase, liarozole, mediated, MEKi, mismatch, neutrophilia, nonessential, NPS, occlusion, Occupational, outlined, rash, recurrent, repair, sanitation, score, Shield, solid, telework, thickened, threat, underlying, unique, vast, vigorously, wellbeing, workforce, workplace
Removed:
Academy, Allergy, Expiratory, Federation, Immunological, lung, measured, plc, presently, Questionnaire
Valuein 2020 Q1 filing- Value in 2020 Q2 filing
Original filings
Filing view